Malaria Vaccines Market Revenue Opportunities By Leading Key Players Operating Globally GlaxoSmithKline plc, Sanaria Inc, Nobelpharma Co., Ltd. and Sumaya Biotech

The Global Malaria Vaccines Market is pegged to be valued at US$ 8.5 million in 2018 and is projected to expand at a CAGR of 102.8% during the forecast period (2018-2024), as highlighted in a new report published by Coherent Market Insights. Rise in demand for vaccines for important indications on the backdrop of increasing focus on biological preparations is expected to be a major factor driving growth of the global malaria vaccines market over the foreseeable future.

Download PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/37

Nearly half of the global population is at risk of malaria as per stats released by the World Health Organization (WHO). This in turn has led to increased inclination of various healthcare agencies towards addressing this major malady. Global non-profit organizations such as the Melinda Gates Foundation and PATH are working towards developing preventive measures and saving lives of many in the malaria affected regions. Africa accounts for the largest number of malaria cases and hence, this region is the primary target of launching the first malaria vaccine developed by GlaxoSmithKline plc. Mosquirix received EU approval in 2015 and is presently being examined in Africa as a pilot study.

Malaria Vaccines Market- Key Players Operating Globally:
Some of the major players involved in global malaria vaccines market are GlaxoSmithKline plc, Sanaria Inc, Nobelpharma Co., Ltd., Sumaya Biotech and GenVec, Inc.

Tremendous potential in the malaria vaccines market

Potential for malaria vaccines is estimated to be huge as a large share of population, 90%-95%, at risk of infection in Africa and South East-Asia. Advent of vaccines for adult population, would be a major breakthrough for the malaria vaccines market. Below are certain alarming statistics that embarks the need for a malaria vaccine:

• Artemisinin resistance has been detected in five countries – Laos, Cambodia, Myanmar, Vietnam and Thailand
• Resistance to P. falciparum parasite against the most available anti-malarial medicines is being reported
• According to the National Vector Borne Disease Control Programme, nearly 95% of the population in India reside in malaria endemic areas
• There were an estimated 214 million malaria cases globally in 2015 (WHO)
• Africa is the most affected region with 90% of malarial deaths in 2015 reported in Africa (WHO)
• Pregnant women, children below 5 years of age, and tourists from countries with low incidence rate of malaria are identified as the most susceptible target population for malaria

Request for Customization of Research Report:
https://www.coherentmarketinsights.com/insight/request-customization/37

Key takeaways of the malaria vaccines market:

• The global malaria vaccines market is expected to expand at a CAGR of 102.8% during the forecast period (2016–2024) as there exists a large unrealized market especially in Africa, Asia Pacific, Latin America and Middle East
• The Pre-Erythrocytic Vaccine dominates the market in the vaccines type segment, as it is used to prevent the infection completely, while blood-stage vaccines aim to reduce or eliminate the parasite load once a person is infected
• Plasmodium Falciparum is the major agent segment of malaria vaccines market, as Plasmodium falciparum infection are induced by the asexual stages of the parasite that develop inside red blood cells, making it one of most severe forms of malaria among various types of parasites causing malaria
• Some of the major players involved in global malaria vaccines market are GlaxoSmithKline plc, Sanaria Inc, Nobelpharma Co., Ltd., Sumaya Biotech and GenVec, Inc.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.